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Background 	

We report here our discovery and whole genome sequencing 
(WGS)  analysis  of  a  family  with  dominantly  inherited 
familial  dysautonomia  (Figure  1).  The  mother  is  affected 
with  dysautonomia,  hereditary  hemochromatosis,  and 
obsessive  compulsive  traits.  The  oldest  daughter  reports 
severe  dysautonomic  syncopal  episodes,  gastroparesis, 
glaucoma,  visual  and  auditory  hallucinations,  urinary 
retention,  and  one  prior  stroke.  One  son  is  affected  with 
dysautonomia,  Tourette  syndrome  (TS),  attention  deficit 
disorder (ADD), and obsessive-compulsive disorder (OCD). 
Another  son  reports  dysautonomia,  asthma,  seizure  in 
response to pertussis, dyslexia, migraine, dysgraphia, ADD, 
sensory integration disorder, and arthritis. 	
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Methods 	

WGS was performed on two affected siblings in the Illumina CLIA-
certified lab. Three other DNA samples from the family also underwent 
WGS in the research setting at CSHL. DNA samples from the same five 
people were genotyped using the Illumina HumanOmni2.5-8 BeadChip. 
Genome-wide parametric linkage analysis was performed using Merlin 
(adjusted for linkage disequilibrium). Our group previously reported the 
low concordance rates across different variant calling pipelines. Thus, to 
reduce algorithm-induced biases, we used multiple pipelines for quality 
control,  alignment,  assembly,  variant  calling,  genotype  refinement, 
variant  filtering,  and  variant  annotation  (Figure  2).  The  Empowered 
Genome Cohort data,   implemented in the Ingenuity variant analysis 
system,  was  also  used  to  filter  out  WGS-specific  sequencing  errors, 
which might have been identified as rare variants. 	

Results  	

Linkage  analysis  showed  not  enough  power  for  identifying  any  disease 
relevant variant loci in a single family. None of the family members carry 
any previously reported variants in IKBKAP that have been implicated in the 
autosomal recessive transmission of familial dysautonomia. The WGS data 
had good sequence coverage for IKBKAP in all five people (mean coverage 
~40x) but we did not identify any novel rare variants in this gene. ERDS and 
PennCNV did not reveal any CNVs that of relevance to the phenotype of 
familial dysautonomia. We have generated a list of rare variants of unknown 
significance (Table 1 & 2). Sanger sequencing results confirmed an insertion 
in  POU4F1  (Figure  4).  We  find  relatively  low  concordance  across  three 
variant detection pipelines (Figure 5). Pharmacogenomic analyses reveal the 
recommended dosages of Coumadin and Simvastatin (Table 3). Five variants 
in three people with prior clinical evidence are also shown (Table 4).	

Conclusions	

Here  we  show one  example  of  individualized  medicine  in  a  family  with 
neuropsychiatric symptoms and at least two rare diseases. WGS data provides 
much more clinically relevant and potentially actionable information when 
compared to genotyping arrays. Despite limited overall agreement between 
CLIA certified and non-CLIA certified analysis pipelines, utilizing variants 
identified by two or more pipelines enables WGS to act as a useful technique 
for clinical diagnostics. For rare diseases, we argue that family history and 
other  family  members’  sequencing  data  should  be  incorporated  into 
downstream analyses so as  to  eliminate false positive findings of  disease-
associated variants. We highlight the importance of detailed phenotyping and 
sharing  of  both  genomic  and  phenotyping  data  because  of  extreme 
heterogeneity  across  families  and  insufficient  knowledge  of  rare  diseases. 
Ongoing effort will focus on identifying and proving familial dysautonomia 
relevant  variants,  extending  the  pharmacogenomic  analyses  to  the  other 
people in the pedigree, and including more family members in our study.	
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Figure 2. The left-hand side is the major analysis work flow while the right-hand side are the details of each 
procedure.* CADD (Combined Annotation Dependent Depletion, in press) : http://cadd.gs.washington.edu/ 	

* Scalpel (in preparation) : Haplotype Micro-assembly for accurate INDEL detection: http://schatzlab.cshl.edu/	
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Figure 1. The pedigree in this study. The numbers below the children are their 
corresponding ages. Five people in the family have thus far been included in our WGS 
study: the parents, the 24-year-old daughter, the 17-year-old son, and the 15-year-old 
daughter.	
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Figure 5. Venn diagrams of the variant calling results across three independent alignment and assembly 
combinations. 2x100 paired end reads for the WGS data were generated on Illumina HiSeq2000 platform. 
Reads were mapped to the hg19 reference genome. BWA-0.7.5a, GATK v.2.6-5, ELANDv2e, and CASAVA 
1.8 were used here. (A) The Venn diagram is for SNP detection comparison. We noticed an even lower 
concordance rate compared to what we previously reported (57.4% across 5 pipelines). This is because we 
here use three different alignment steps. (B) The Venn diagram is for INDEL detection, the concordance rate 
is even lower: 40.6%. We focus on variants called by at least two pipelines, i.e. the central region surrounded 
by the red dash lines. This allows us to analyze 82.6% of the SNPs and 72.9% of the INDELs in our 
downstream analyses. 	
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Table 3. Recommended dosages for Coumadin and Simvastatin dosages based on the oldest daughter's WGS 
results, in comparison to what she was actually prescribed in the absence of any genetic testing. 
Pharmacogenomics analyses were performed based on guidelines and algorithms from the International Warfarin 
Pharmarcogenomics Consortium (IWPC) and the Clinical Pharmacogenomics Implementation Consortium (CPIC) 
in the PharmGKB database. People who are homozygous for major alleles at both sites in CYP2C9 are designated 
as *1/*1. 	

Table 1. A subset list of rare variants (MAF < 1%) found in at least two affected people. 
These variants are called by at least two pipelines, within coding regions, with a high 
VAAST score, and a CADD c-score greater than 20. 	
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Table 2. The insertion in POU4F1 is found in two children with familial dysautonomia. 
There is no coverage in the mother’s WGS data. Follow-up Sanger sequencing confirmed 
the existence of the homozygous insertion in all three people : affected mother, affected 
daughter, and affected son. POU4F1 encodes a member of the POU-IV class of neural 
transcription factors. This protein is expressed in a subset of retinal ganglion cells and 
may be involved in the developing sensory nervous system.	

Table 4. At least seven mutations with substantial clinical relevance were found in our study. The “Daughter” means 
the oldest daughter, and the “Son” means  the 17-year-old son. “hom” = homozygous and “het” = heterozygous. 
“WT” = wild type. The mother is homozygous for the C282Y variant in HFE, and, consistent with the lack of 
symptoms for hemochromatosis in the children, we found that all three children are carriers for the C282Y variant, 
but not carrying any other reported hemochromatosis related variants. 	

Figure 4. Sanger sequencing results confirmed the homozygous insertion in exon 2 of 
POU4F1. Sanger sequencing results of (A) the mother, (B) the oldest daughter, and (C) 
the 17-year-old son.	
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Gene Chr Position Region Transcript Variant Protein Variant Inferred Activity
POU4F1 13 79176323 Exonic c.484_486dipGGC p.162_163_ins Loss
Drug Recommend dosages based on 
genotypes
Previous 
prescriptions
FDA 
recommendations
Genotypes
Coumadin 
(Warfarin 
Sodium)
5.85 mg/day 5 mg/day
2 to 10 mg daily
Consider genetic 
testing results
VKORC1: A/G
(rs9923231)
CYP2C9: *1/*1
(rs1799853, rs1057910)
Simvastatin
20 mg/day
Increased risk of myopathy with 
40 mg Simvastatin
20 mg/day 80 mg/day SLCO1B1: T/C(rs4149056)
Gene
name
Genomic
coordinates
Amino Acid
change
Zygosity
Effect
Quality
Coverage
Population
frequency
EPS15 chr1:51829571 Gly>Arg
Heterozygous
non-synon
197
47:24:23 Unknown
MYL7 chr7: 44179406 Gly>Ser
Heterozygous
non-synon
71
23:16:7 0.69%
ERI1 chr8: 8865561 Pro>Ser
Heterozygous
non-synon
156
49:30:19 Unknown
CCIN chr9: 36170317 Arg>Gln
Heterozygous
non-synon
223
36:14:22 0.14%
PCTP chr17: 53844742 Cys>Tyr
Heterozygous
non-synon
223
47:22:25 0.98%
